Free Trial
OTCMKTS:MKKGY

Merck KGaA (MKKGY) Stock Price, News & Analysis

Merck KGaA logo
$26.50 +0.51 (+1.96%)
As of 05/27/2025 03:53 PM Eastern

About Merck KGaA Stock (OTCMKTS:MKKGY)

Key Stats

Today's Range
$26.42
$26.66
50-Day Range
$24.36
$28.49
52-Week Range
$24.32
$39.17
Volume
159,826 shs
Average Volume
132,082 shs
Market Capitalization
$17.12 billion
P/E Ratio
16.36
Dividend Yield
1.25%
Price Target
N/A
Consensus Rating
Buy

Company Overview

Merck KGaA operates as a science and technology company in Germany. It operates through Life Science, Healthcare, and Electronics segments. The company's Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers, as well as industrial sector. This segment provides drug manufacturers with process development expertise and technologies, such as continuous bioprocessing; testing kits and services; reagents and services; testing solutions that analyze air, water, and soil; and testing and tools, as well as products that help test nutritional value and identify quality inconsistencies. Its Healthcare segment discovers, develops, manufacturers, and markets prescription drugs and biopharmaceuticals for the treatment of oncology, neurology and immunology, fertility, endocrinology, as well as cardiovascular, diabetes, thyroid disorders, and multiple sclerosis; general medicines; and injection device and disease monitoring software. The Electronics segment supplies materials for the semiconductor and display industries and surface design, such as delivery systems and services, as well as surface solutions, including cosmetics, effect pigments, and functional solutions. In addition, it has in-licensing agreement with Debiopharm International SA for developing and commercializing drug candidates for the treatment of head and neck cancer; Jiangsu Hengrui Pharmaceuticals Co. Ltd. for developing, manufacturing, and commercializing drug candidates for the treatment of metastatic colorectal cancer; and Abbisko Therapeutics Co. Ltd. for developing and commercializing of drug candidates for the treatment of tenosynovial giant cell tumor, as well as license and collaboration agreement with Merck KGaA to discover two targeted protein degraders against critical oncogenic proteins. The company was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA operates as a subsidiary of E. Merck KGaA.

Merck KGaA Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
58th Percentile Overall Score

MKKGY MarketRank™: 

Merck KGaA scored higher than 58% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Earnings Growth

    Earnings for Merck KGaA are expected to grow by 9.63% in the coming year, from $1.87 to $2.05 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Merck KGaA is 16.36, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 24.77.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Merck KGaA is 16.36, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 27.03.

  • Price to Earnings Growth Ratio

    Merck KGaA has a PEG Ratio of 2.05. PEG Ratios above 1 indicate that a company could be overvalued.

  • Read more about Merck KGaA's valuation and earnings.
  • Percentage of Shares Shorted

    0.01% of the outstanding shares of Merck KGaA have been sold short.
  • Short Interest Ratio / Days to Cover

    Merck KGaA has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Merck KGaA has recently decreased by 36.92%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Merck KGaA pays a meaningful dividend of 1.27%, higher than the bottom 25% of all stocks that pay dividends.

  • Dividend Growth

    Merck KGaA does not have a long track record of dividend growth.

  • Dividend Coverage

    The dividend payout ratio of Merck KGaA is 15.64%. This payout ratio is at a healthy, sustainable level, below 75%.

  • Dividend Sustainability

    Based on earnings estimates, Merck KGaA will have a dividend payout ratio of 16.10% next year. This indicates that Merck KGaA will be able to sustain or increase its dividend.

  • Read more about Merck KGaA's dividend.
  • Percentage of Shares Shorted

    0.01% of the outstanding shares of Merck KGaA have been sold short.
  • Short Interest Ratio / Days to Cover

    Merck KGaA has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Merck KGaA has recently decreased by 36.92%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Merck KGaA has a news sentiment score of 0.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.03 average news sentiment score of Medical companies.
  • Search Interest

    2 people have searched for MKKGY on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Merck KGaA insiders have not sold or bought any company stock.

  • Percentage Held by Institutions

    Only 0.10% of the stock of Merck KGaA is held by institutions.

  • Read more about Merck KGaA's insider trading history.
Receive MKKGY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Merck KGaA and its competitors with MarketBeat's FREE daily newsletter.

MKKGY Stock News Headlines

July 2025 Rule Change to Impact Retirement Investors
There's a massive change from a new rule going into effect this July. And it's one the Big Banks are already using to their advantage… It allows them to treat this new asset like actual cash.
See More Headlines

MKKGY Stock Analysis - Frequently Asked Questions

Merck KGaA's stock was trading at $28.63 on January 1st, 2025. Since then, MKKGY stock has decreased by 7.4% and is now trading at $26.50.
View the best growth stocks for 2025 here
.

Merck KGaA (OTCMKTS:MKKGY) issued its quarterly earnings data on Thursday, May, 15th. The company reported $0.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.50 by $0.09. The firm had revenue of $5.89 billion for the quarter, compared to analysts' expectations of $5.32 billion. Merck KGaA had a trailing twelve-month return on equity of 10.41% and a net margin of 12.89%.

Shares of MKKGY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Ex-Dividend for 5/7 Dividend
4/29/2025
Record date for 5/7 Dividend
4/30/2025
Dividend Payable
5/07/2025
Last Earnings
5/15/2025
Today
5/27/2025
Next Earnings (Estimated)
8/07/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
OTCMKTS:MKKGY
Previous Symbol
OTCMKTS:MKKGY
CIK
N/A
Employees
62,908
Year Founded
N/A

Profitability

Trailing P/E Ratio
16.36
Forward P/E Ratio
14.17
P/E Growth
2.05
Net Income
$3.06 billion
Pretax Margin
16.09%

Debt

Sales & Book Value

Annual Sales
$22.72 billion
Cash Flow
$9.67 per share
Price / Cash Flow
2.74
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
$17.12 billion
Optionable
Not Optionable
Beta
0.96
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (OTCMKTS:MKKGY) was last updated on 5/28/2025 by MarketBeat.com Staff
From Our Partners